Thomas Bo Jensen
Research Subjects
Thomas Bo Jensen has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Gunnar Hilmar Gislason
Department of Cardiology, Copenhagen University Hospital, Herlev and Gentofte , Hospitalsvej 1, 2900 Hellerup
9 shared publications - Espen Jimenez-Solem
Department of Clinical Pharmacology, Bispebjerg Hospital, Copenhagen, Denmark
7 shared publications Christian Torp-Pedersen
Department of Health Science and Technology, Aalborg University, Aalborg, Denmark
5 shared publications- Michelle Dalgas Schmiegelow
Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark
5 shared publications Charlotte Andersson
Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark
4 shared publications- Tonny Studsgaard Petersen
Department of Clinical Medicine, University of Copenhagen
4 shared publications
Latest Publications
- Open Access
- 10 July 2024
- Published by Springer Nature in Diabetologia
- Vol. 67 (9) , 1783-1799
Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial
Aims/hypothesis: The aim of this study was to evaluate the efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes insufficiently controlled with diet and exercise alone. Methods: The Peptide Innovation for Early Diabetes Treatment (PIONEER) 11 trial was a double-blind, randomised, Phase IIIa trial conducted across 52 sites in the China region (mainland China and Taiwan), Hungary, Serbia and Ukraine. Eligible participants were ≥18 years (≥20 years in Taiwan), had a diagnosis of type 2 diabetes with HbA1c 53–86 mmol/mol (7.0–10.0%) and were not receiving any glucose-lowering drugs. After a 4-week run-in period in which participants were treated with diet and exercise alone, those who fulfilled the randomisation criteria were randomised (1:1:1:1) using a web-based randomisation system to receive once-daily oral semaglutide 3 mg, 7 mg or 14 mg or placebo for 26 weeks (using a 4-week dose-escalation regimen for the higher doses). Randomisation was stratified according to whether participants were from the China region or elsewhere. The primary and confirmatory secondary endpoints were change from baseline to week 26 in HbA1c and body weight (kg), respectively. Safety was assessed in all participants exposed to at least one dose of the trial product. Results: Between October 2019 and October 2021, a total of 774 participants were screened and 521 participants were randomised to oral semaglutide 3 mg (n=130), 7 mg (n=130), 14 mg (n=130) or placebo (n=131); most participants (92.5%, n=482) completed the trial, with 39 participants prematurely discontinuing treatment. The number of participants contributing to the trial analyses was based on the total number of participants who were randomised at the beginning of the trial. The majority of participants were male (63.7%), and the mean age of participants was 52 years. At baseline, mean HbA1c and body weight were 63 mmol/mol (8.0%) and 79.6 kg, respectively. Oral semaglutide resulted in significantly greater reductions in HbA1c than placebo at week 26 (ppp1c and body weight were observed in the Chinese subpopulation, which represented 74.9% of participants in the overall population. Adverse events (AEs) occurred in between 65.4% and 72.3% of participants receiving oral semaglutide (for all doses) and 57.3% of participants with placebo. Most AEs were mild to moderate in severity, with few serious AEs reported; the most commonly reported AEs were gastrointestinal-related and were more frequent with semaglutide (all doses) than with placebo. The proportion of AEs was slightly higher in the Chinese subpopulation. Conclusions/interpretation: Oral semaglutide resulted in significantly greater reductions in HbA1c across all doses and in significant body weight reductions for the 7 mg and 14 mg doses when compared with placebo in predominantly Chinese participants with type 2 diabetes insufficiently controlled by diet and exercise alone. Oral semaglutide was generally well tolerated, with a safety profile consistent with that seen in the global PIONEER trials. Trial registration: ClinicalTrials.gov NCT04109547. Funding: Novo Nordisk A/S. Graphical
- 10 July 2024
- Published by Springer Nature in Diabetologia
- Vol. 67 (9) , 1783-1799
Open AccessEfficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial
Aims/hypothesis: The aim of this study was to evaluate the efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes insufficiently controlled with diet and exercise alone. Methods: The Peptide Innovation for Early Diabetes Treatment (PIONEER) 11 trial was a double-blind, randomised, Phase IIIa trial conducted across 52 sites in the China region (mainland China and Taiwan), Hungary, Serbia and Ukraine. Eligible participants were ≥18 years (≥20 years in Taiwan), had a diagnosis of type 2 diabetes with HbA1c 53–86 mmol/mol (7.0–10.0%) and were not receiving any glucose-lowering drugs. After a 4-week run-in period in which participants were treated with diet and exercise alone, those who fulfilled the randomisation criteria were randomised (1:1:1:1) using a web-based randomisation system to receive once-daily oral semaglutide 3 mg, 7 mg or 14 mg or placebo for 26 weeks (using a 4-week dose-escalation regimen for the higher doses). Randomisation was stratified according to whether participants were from the China region or elsewhere. The primary and confirmatory secondary endpoints were change from baseline to week 26 in HbA1c and body weight (kg), respectively. Safety was assessed in all participants exposed to at least one dose of the trial product. Results: Between October 2019 and October 2021, a total of 774 participants were screened and 521 participants were randomised to oral semaglutide 3 mg (n=130), 7 mg (n=130), 14 mg (n=130) or placebo (n=131); most participants (92.5%, n=482) completed the trial, with 39 participants prematurely discontinuing treatment. The number of participants contributing to the trial analyses was based on the total number of participants who were randomised at the beginning of the trial. The majority of participants were male (63.7%), and the mean age of participants was 52 years. At baseline, mean HbA1c and body weight were 63 mmol/mol (8.0%) and 79.6 kg, respectively. Oral semaglutide resulted in significantly greater reductions in HbA1c than placebo at week 26 (ppp1c and body weight were observed in the Chinese subpopulation, which represented 74.9% of participants in the overall population. Adverse events (AEs) occurred in between 65.4% and 72.3% of participants receiving oral semaglutide (for all doses) and 57.3% of participants with placebo. Most AEs were mild to moderate in severity, with few serious AEs reported; the most commonly reported AEs were gastrointestinal-related and were more frequent with semaglutide (all doses) than with placebo. The proportion of AEs was slightly higher in the Chinese subpopulation. Conclusions/interpretation: Oral semaglutide resulted in significantly greater reductions in HbA1c across all doses and in significant body weight reductions for the 7 mg and 14 mg doses when compared with placebo in predominantly Chinese participants with type 2 diabetes insufficiently controlled by diet and exercise alone. Oral semaglutide was generally well tolerated, with a safety profile consistent with that seen in the global PIONEER trials. Trial registration: ClinicalTrials.gov NCT04109547. Funding: Novo Nordisk A/S. Graphical
- Open Access
- 28 June 2023
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 62 (7) , 1045-1047
Correction to: Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects
- 28 June 2023
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 62 (7) , 1045-1047
Open AccessCorrection to: Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects
- Open Access
- 17 March 2023
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 62 (4) , 635-644
Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects
Background Prescribing information instructs taking oral semaglutide (a glucagon-like peptide-1 analogue) in the fasting state, followed by a post-dose fasting period of ≥ 30 min. This trial compared the recommended dosing schedule with alternative schedules. Methods This was a randomised, single-centre, multiple-dose, open-label, five-armed, parallel-group trial in healthy subjects who received once-daily oral semaglutide (3 mg for 5 days followed by 7 mg for 5 days). Subjects (n = 156) were randomised to five dosing schedules: 2-, 4-, or 6-h pre-dose fast followed by a 30-min post-dose fast (treatment arms: 2 h–30 min, 4–30 min, 6 h–30 min); 2-h pre-dose fast followed by an overnight post-dose fast (treatment arm: 2 h–night); or overnight pre-dose fast followed by a 30-min post-dose fast (reference arm: night–30 min). Semaglutide plasma concentration was measured regularly until 24 h after the 10th dose. Endpoints included area under the semaglutide plasma concentration–time curve during a 24-h interval after the 10th dose (AUC0–24h) (primary endpoint) and maximum observed semaglutide plasma concentration after the 10th dose (Cmax) (secondary endpoint). Results Compared with an overnight pre-dose fast (reference arm: night–30 min), shorter pre-dose fasting times in the 2 h–night, 2 h–30 min, 4 h–30 min, and 6 h–30 min treatment arms resulted in significantly lower semaglutide AUC0–24h and Cmax after the 10th dose (estimated treatment ratio ranges: 0.12–0.43 and 0.11–0.44, respectively; p < 0.0001 for all comparisons). Semaglutide AUC0–24h and Cmax after the 10th dose were similar for the 2 h–30 min and 2 h–night treatment arms. Conclusion This trial supports dosing oral semaglutide in accordance with prescribing information, which requires dosing in the fasting state. Trial Registration ClinicalTrials.gov (NCT04513704); registered August 14, 2020.
- 17 March 2023
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 62 (4) , 635-644
Open AccessEffect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects
Background Prescribing information instructs taking oral semaglutide (a glucagon-like peptide-1 analogue) in the fasting state, followed by a post-dose fasting period of ≥ 30 min. This trial compared the recommended dosing schedule with alternative schedules. Methods This was a randomised, single-centre, multiple-dose, open-label, five-armed, parallel-group trial in healthy subjects who received once-daily oral semaglutide (3 mg for 5 days followed by 7 mg for 5 days). Subjects (n = 156) were randomised to five dosing schedules: 2-, 4-, or 6-h pre-dose fast followed by a 30-min post-dose fast (treatment arms: 2 h–30 min, 4–30 min, 6 h–30 min); 2-h pre-dose fast followed by an overnight post-dose fast (treatment arm: 2 h–night); or overnight pre-dose fast followed by a 30-min post-dose fast (reference arm: night–30 min). Semaglutide plasma concentration was measured regularly until 24 h after the 10th dose. Endpoints included area under the semaglutide plasma concentration–time curve during a 24-h interval after the 10th dose (AUC0–24h) (primary endpoint) and maximum observed semaglutide plasma concentration after the 10th dose (Cmax) (secondary endpoint). Results Compared with an overnight pre-dose fast (reference arm: night–30 min), shorter pre-dose fasting times in the 2 h–night, 2 h–30 min, 4 h–30 min, and 6 h–30 min treatment arms resulted in significantly lower semaglutide AUC0–24h and Cmax after the 10th dose (estimated treatment ratio ranges: 0.12–0.43 and 0.11–0.44, respectively; p < 0.0001 for all comparisons). Semaglutide AUC0–24h and Cmax after the 10th dose were similar for the 2 h–30 min and 2 h–night treatment arms. Conclusion This trial supports dosing oral semaglutide in accordance with prescribing information, which requires dosing in the fasting state. Trial Registration ClinicalTrials.gov (NCT04513704); registered August 14, 2020.
- 1 October 2021
- Published by British Editorial Society of Bone & Joint Surgery in The Bone & Joint Journal
- Vol. 103-B (10) , 1571-1577
Thromboembolic and bleeding complications following primary total knee arthroplasty
Aims: The aim of this study is to compare the effectiveness and safety of thromboprophylactic treatments in patients undergoing primary total knee arthroplasty (TKA). Methods: Using nationwide medical registries, we identified patients with a primary TKA performed in Denmark between 1 January 2013 and 31 December 2018 who received thromboprophylactic treatment. We examined the 90-day risk of venous thromboembolism (VTE), major bleeding, and all-cause mortality following surgery. We used a Cox regression model to compute hazard ratios (HRs) with 95% confidence intervals (CIs) for each outcome, pairwise comparing treatment with dalteparin or dabigatran with rivaroxaban as the reference. The HRs were both computed using a multivariable and a propensity score matched analysis. Results: We identified 27,736 primary TKA patients who received thromboprophylactic treatment (rivaroxaban (n = 18,846); dalteparin (n = 5,767); dabigatran (n = 1,443); tinzaparin (n = 1,372); and enoxaparin (n = 308)). In the adjusted multivariable analysis and compared with rivaroxaban, treatment with dalteparin (HR 0.68 (95% CI 0.49 to 0.92)) or dabigatran (HR 0.31 (95% CI 0.13 to 0.70)) was associated with a decreased risk of VTE. No statistically significant differences were observed for major bleeding or all-cause mortality. The propensity score matched analysis yielded similar results. Conclusion: Treatment with dalteparin or dabigatran was associated with a decreased 90-day risk of VTE following primary TKA surgery compared with treatment with rivaroxaban. Cite this article: Bone Joint J 2021;103-B(10):1571–1577.
- 1 October 2021
- Published by British Editorial Society of Bone & Joint Surgery in The Bone & Joint Journal
- Vol. 103-B (10) , 1571-1577
Thromboembolic and bleeding complications following primary total knee arthroplasty
Aims: The aim of this study is to compare the effectiveness and safety of thromboprophylactic treatments in patients undergoing primary total knee arthroplasty (TKA). Methods: Using nationwide medical registries, we identified patients with a primary TKA performed in Denmark between 1 January 2013 and 31 December 2018 who received thromboprophylactic treatment. We examined the 90-day risk of venous thromboembolism (VTE), major bleeding, and all-cause mortality following surgery. We used a Cox regression model to compute hazard ratios (HRs) with 95% confidence intervals (CIs) for each outcome, pairwise comparing treatment with dalteparin or dabigatran with rivaroxaban as the reference. The HRs were both computed using a multivariable and a propensity score matched analysis. Results: We identified 27,736 primary TKA patients who received thromboprophylactic treatment (rivaroxaban (n = 18,846); dalteparin (n = 5,767); dabigatran (n = 1,443); tinzaparin (n = 1,372); and enoxaparin (n = 308)). In the adjusted multivariable analysis and compared with rivaroxaban, treatment with dalteparin (HR 0.68 (95% CI 0.49 to 0.92)) or dabigatran (HR 0.31 (95% CI 0.13 to 0.70)) was associated with a decreased risk of VTE. No statistically significant differences were observed for major bleeding or all-cause mortality. The propensity score matched analysis yielded similar results. Conclusion: Treatment with dalteparin or dabigatran was associated with a decreased 90-day risk of VTE following primary TKA surgery compared with treatment with rivaroxaban. Cite this article: Bone Joint J 2021;103-B(10):1571–1577.
- 14 October 2020
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 128 (3) , 455-462
Validation of registration of pharmacological treatment in the Danish Hip and Knee Arthroplasty Registers
The aim of this study was to validate registration of pharmacological treatment in the Danish Hip Arthroplasty Register (DHR) and Danish Knee Arthroplasty Register (DKR). We conducted a population‐based study in the Capital Region of Denmark, January 2012 to April 2016. Positive predictive value (PPV) and sensitivity were calculated with 95% confidence intervals (CI) for antithrombotic, antihemorrhagic, and antibiotic treatment registered in the DHR and DKR using electronic health records as the reference standard. For the DHR, the PPV and sensitivity were 77.9% (95% CI: 77.2 to 78.6) and 99.6% (95% CI: 99.4 to 99.7) for antithrombotic treatment, 70.9% (95% CI: 70.1 to 71.7) and 97.4% (95% CI: 97.1 to 97.7) for antihemorrhagic treatment, and 82.9% (95% CI: 82.2 to 83.5) and 99.4% (95% CI: 99.3 to 99.5) for antibiotic treatment, respectively. For the DKR, the PPV and sensitivity were 80.6% (95% CI: 79.8 to 81.4) and 99.6% (95% CI: 99.4 to 99.7) for antithrombotic treatment, and 84.4% (95% CI: 83.7 to 85.1) and 100.0% (95% CI: 99.9 to 100.0) for antibiotic treatment, respectively. The PPV and sensitivity for overall pharmacological treatment registered in the DHR and DKR were generally high and acceptable for use in research.
- 14 October 2020
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 128 (3) , 455-462
Validation of registration of pharmacological treatment in the Danish Hip and Knee Arthroplasty Registers
The aim of this study was to validate registration of pharmacological treatment in the Danish Hip Arthroplasty Register (DHR) and Danish Knee Arthroplasty Register (DKR). We conducted a population‐based study in the Capital Region of Denmark, January 2012 to April 2016. Positive predictive value (PPV) and sensitivity were calculated with 95% confidence intervals (CI) for antithrombotic, antihemorrhagic, and antibiotic treatment registered in the DHR and DKR using electronic health records as the reference standard. For the DHR, the PPV and sensitivity were 77.9% (95% CI: 77.2 to 78.6) and 99.6% (95% CI: 99.4 to 99.7) for antithrombotic treatment, 70.9% (95% CI: 70.1 to 71.7) and 97.4% (95% CI: 97.1 to 97.7) for antihemorrhagic treatment, and 82.9% (95% CI: 82.2 to 83.5) and 99.4% (95% CI: 99.3 to 99.5) for antibiotic treatment, respectively. For the DKR, the PPV and sensitivity were 80.6% (95% CI: 79.8 to 81.4) and 99.6% (95% CI: 99.4 to 99.7) for antithrombotic treatment, and 84.4% (95% CI: 83.7 to 85.1) and 100.0% (95% CI: 99.9 to 100.0) for antibiotic treatment, respectively. The PPV and sensitivity for overall pharmacological treatment registered in the DHR and DKR were generally high and acceptable for use in research.
- Open Access
- 13 July 2020
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 128 (1) , 46-51
How patients in Denmark acquire their medicines: overview, data sources and implications for pharmacoepidemiology
The means by which patients acquire their medications differ between countries, and a knowledge of this is essential when conducting and interpreting pharmacoepidemiological studies. The aim of this paper is to provide an overview of how patients obtain medicines in Denmark, to relate these to nationwide registries available for research and to discuss the implications for research. Health services are predominantly tax‐funded in Denmark, with dentistry and some medicine bought at community pharmacies being exceptions, involving partial reimbursement of charges. The paper gives an overview of prescription medicines acquired from community pharmacies (including magistral preparations), over‐the‐counter medicines, vaccinations and in‐hospital medicine including so‐called “free medicine” (in Danish: “vederlagsfri medicin”). “Free medicine” is medicines for a defined list of diseases and indications that is provided free of charge to patients in outpatient clinics. The paper also describes the content of the various Danish data sources about medicine use, summarizes their strengths and limitations, and exemplifies the ways of evaluating their completeness. An example is provided of the regional variation in the means by which medicines are acquired.
- 13 July 2020
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 128 (1) , 46-51
Open AccessHow patients in Denmark acquire their medicines: overview, data sources and implications for pharmacoepidemiology
The means by which patients acquire their medications differ between countries, and a knowledge of this is essential when conducting and interpreting pharmacoepidemiological studies. The aim of this paper is to provide an overview of how patients obtain medicines in Denmark, to relate these to nationwide registries available for research and to discuss the implications for research. Health services are predominantly tax‐funded in Denmark, with dentistry and some medicine bought at community pharmacies being exceptions, involving partial reimbursement of charges. The paper gives an overview of prescription medicines acquired from community pharmacies (including magistral preparations), over‐the‐counter medicines, vaccinations and in‐hospital medicine including so‐called “free medicine” (in Danish: “vederlagsfri medicin”). “Free medicine” is medicines for a defined list of diseases and indications that is provided free of charge to patients in outpatient clinics. The paper also describes the content of the various Danish data sources about medicine use, summarizes their strengths and limitations, and exemplifies the ways of evaluating their completeness. An example is provided of the regional variation in the means by which medicines are acquired.
- Open Access
- 1 June 2020
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 180 (6) , 902-903
Shift From Adalimumab Originator to Biosimilars in Denmark
Brand-name adalimumab (Humira, hereinafter originator) is by far the most cost-intensive pharmaceutical product in the US with global sales of $19.9 billion in 2018.1 Five adalimumab biosimilars have been approved by the US Food and Drug Administration, but none are marketed owing to patent disputes. The first to become marketed is expected in January 2023.2 A 2019 Viewpoint argues that cost savings in the US due to adalimumab biosimilars might vanish as patients might switch to newer and better drugs before the biosimilars become available.3 The lack of adalimumab biosimilars results in substantial premiums being paid by patients and payers when much cheaper biosimilar drugs are available outside the US.
- 1 June 2020
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 180 (6) , 902-903
Open AccessShift From Adalimumab Originator to Biosimilars in Denmark
Brand-name adalimumab (Humira, hereinafter originator) is by far the most cost-intensive pharmaceutical product in the US with global sales of $19.9 billion in 2018.1 Five adalimumab biosimilars have been approved by the US Food and Drug Administration, but none are marketed owing to patent disputes. The first to become marketed is expected in January 2023.2 A 2019 Viewpoint argues that cost savings in the US due to adalimumab biosimilars might vanish as patients might switch to newer and better drugs before the biosimilars become available.3 The lack of adalimumab biosimilars results in substantial premiums being paid by patients and payers when much cheaper biosimilar drugs are available outside the US.
- Open Access
- 5 March 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-8
Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years
Treatment guidelines for type 2 diabetes (T2D) recommend avoidance of hypoglycemia and less stringent glycemic control in older patients. We examined the relation of glycemic control to glucose-lowering medications use in a cohort of patients aged>80 years with a diagnosis of T2D and a hospital admission in the Capital Region of Denmark in 2012–2016. We extracted data on medication use, diagnoses, and biochemistry from the hospitals’ records. We identified 5,172 T2D patients with high degree of co-morbidity and where 17% had an HbA1c in the range recommended for frail, comorbid, older patients with type 2 diabetes (58–75 mmol/mol (7.5–9%)). Half of the patients (n = 2,575) had an HbA1c 1c-values 1c values 1c within the generally recommended glycemic targets. One third of patients did not meet the diagnostic criteria for T2D, and of the patients who were treated with glucose-lowering medications, one-fifth had HbA1c-values suggesting overtreatment.
- 5 March 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-8
Open AccessGlycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years
Treatment guidelines for type 2 diabetes (T2D) recommend avoidance of hypoglycemia and less stringent glycemic control in older patients. We examined the relation of glycemic control to glucose-lowering medications use in a cohort of patients aged>80 years with a diagnosis of T2D and a hospital admission in the Capital Region of Denmark in 2012–2016. We extracted data on medication use, diagnoses, and biochemistry from the hospitals’ records. We identified 5,172 T2D patients with high degree of co-morbidity and where 17% had an HbA1c in the range recommended for frail, comorbid, older patients with type 2 diabetes (58–75 mmol/mol (7.5–9%)). Half of the patients (n = 2,575) had an HbA1c 1c-values 1c values 1c within the generally recommended glycemic targets. One third of patients did not meet the diagnostic criteria for T2D, and of the patients who were treated with glucose-lowering medications, one-fifth had HbA1c-values suggesting overtreatment.
- 1 November 2019
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 76 (1) , 35-40
The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars
A rapidly increasing use of biological drugs has led to substantial costs. Shift to biosimilars enables considerable reduction of these costs without jeopardizing the treatment of patients, but most countries have extensive possibilities of untapped cost-savings. The aim of this study was to describe the Danish quick and near-complete implementation of the two first TNF inhibitor biosimilars (infliximab and etanercept).
- 1 November 2019
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 76 (1) , 35-40
The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars
A rapidly increasing use of biological drugs has led to substantial costs. Shift to biosimilars enables considerable reduction of these costs without jeopardizing the treatment of patients, but most countries have extensive possibilities of untapped cost-savings. The aim of this study was to describe the Danish quick and near-complete implementation of the two first TNF inhibitor biosimilars (infliximab and etanercept).